Cadrenal Therapeutics (CVKD) Earnings Date & Reports
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
CVKD is expected to report earnings to rise 8.40% to -141 cents per share on March 18
Q4'25
Est.
$-1.42
Q3'25
Beat
by $0.08
Q2'25
Missed
by $0.61
Q4'24
Missed
by $1.88
Q3'24
Missed
by $2.06
The last earnings report on November 10 showed earnings per share of -130 cents, beating the estimate of -138 cents. With 17.64K shares outstanding, the current market capitalization sits at 15.70M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CVKD showed earnings on November 10, 2025. You can read more about the earnings report here.